Longbow Research downgraded shares of Cambrex (NYSE:CBM) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports.
A number of other analysts have also weighed in on CBM. Zacks Investment Research upgraded Cambrex from a strong sell rating to a hold rating in a research note on Monday, January 15th. William Blair began coverage on Cambrex in a research note on Tuesday, January 16th. They issued an outperform rating on the stock. Finally, Craig Hallum reiterated a buy rating and issued a $60.00 target price (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. Cambrex presently has a consensus rating of Hold and an average price target of $60.00.
Shares of Cambrex (CBM) opened at $52.80 on Wednesday. Cambrex has a 52 week low of $42.55 and a 52 week high of $62.95. The firm has a market capitalization of $1,737.60, a price-to-earnings ratio of 17.20, a price-to-earnings-growth ratio of 1.28 and a beta of 2.38.
Cambrex (NYSE:CBM) last released its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business had revenue of $182.28 million for the quarter, compared to analyst estimates of $181.39 million. During the same quarter last year, the firm posted $1.23 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. analysts expect that Cambrex will post 2.76 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of the company. William Blair Investment Management LLC grew its position in shares of Cambrex by 35.8% during the 4th quarter. William Blair Investment Management LLC now owns 2,353,032 shares of the biotechnology company’s stock worth $112,946,000 after buying an additional 620,098 shares in the last quarter. We Are One Seven LLC bought a new position in shares of Cambrex during the 4th quarter worth $320,000. MetLife Investment Advisors LLC bought a new position in shares of Cambrex during the 4th quarter worth $729,000. Jane Street Group LLC bought a new position in shares of Cambrex during the 4th quarter worth $235,000. Finally, Flinton Capital Management LLC grew its position in shares of Cambrex by 27.1% during the 4th quarter. Flinton Capital Management LLC now owns 5,100 shares of the biotechnology company’s stock worth $245,000 after buying an additional 1,088 shares in the last quarter.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.